Find, compare & contact
Ropidoxuridine
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ropidoxuridine API 93265-81-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ropidoxuridine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ropidoxuridine
- Synonyms:
- 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE , 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO- , 5-iodo-2-pyrimidinone-2'-deoxyribose , Ropidoxuridine
- Cas Number:
- 93265-81-7
- DrugBank number:
- DB06485
- Unique Ingredient Identifier:
- 3HX21A3SQF
General Description:
Ropidoxuridine, identified by CAS number 93265-81-7, is a notable compound with significant therapeutic applications. Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in cancer/tumors (unspecified). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Classification:
Ropidoxuridine belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2, classified under the direct parent group Pyrimidine 2'-deoxyribonucleosides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the Pyrimidine nucleosides class, specifically within the Pyrimidine 2'-deoxyribonucleosides subclass.
Categories:
Ropidoxuridine is categorized under the following therapeutic classes: Antineoplastic Agents, Nucleic Acids, Nucleotides, and Nucleosides, Nucleosides, Pyrimidines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ropidoxuridine is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
